Cargando…
Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy
Bortezomib is a highly selective, reversible inhibitor of the 26S proteasome that is indicated for single-agent use in the treatment of patients with multiple myeloma who have received at least 2 prior therapies and are progressing on their most recent therapy. Clinical investigations have been comp...
| Autores principales: | , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2005
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1164423/ https://www.ncbi.nlm.nih.gov/pubmed/15929791 http://dx.doi.org/10.1186/1475-2867-5-18 |